ERBB2 and non-small cell lung carcinoma: Based on DESTINY-Lung01, the National Comprehensive Cancer Network (NCCN) granted a category 2A recommendation (preferred over TDM1) for TDXd in previously treated HER2-mutant advanced NSCLC.